Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.

PURPOSE This study tested the hypothesis that highly targeted intrastromal delivery of bevacizumab using coated microneedles allows dramatic dose sparing compared with subconjunctival and topical delivery for treatment of corneal neovascularization. METHODS Stainless steel microneedles 400 μm in length were coated with bevacizumab. A silk suture was placed in the cornea approximately 1 mm from the limbus to induce corneal neovascularization in the eyes of New Zealand white rabbits that were divided into different groups: untreated, microneedle delivery, topical eye drop, and subconjunctival injection of bevacizumab. All drug treatments were initiated 4 days after suture placement and area of neovascularization was measured daily by digital photography for 18 days. RESULTS Eyes treated once with 4.4 μg bevacizumab using microneedles reduced neovascularization compared with untreated eyes by 44% (day 18). Eyes treated once with 2500 μg bevacizumab using subconjunctival injection gave similar results to microneedle-treated eyes. Eyes treated once with 4.4 μg subconjunctival bevacizumab showed no significant effect compared with untreated eyes. Eyes treated with 52,500 μg bevacizumab by eye drops three times per day for 14 days reduced the neovascularization area compared with untreated eyes by 6% (day 18), which was significantly less effective than the single microneedle treatment. Visual exam and histological analysis showed no observable effect of microneedle treatment on corneal transparency or microanatomical structure. CONCLUSIONS This study shows that microneedles can target drug delivery to corneal stroma in a minimally invasive way and demonstrates effective suppression of corneal neovascularization after suture-induced injury using a much lower dose compared with conventional methods.

[1]  B. Ambati,et al.  Mediators of ocular angiogenesis , 2009, Journal of Genetics.

[2]  K. Solomon,et al.  LASIK world literature review: quality of life and patient satisfaction. , 2009, Ophthalmology.

[3]  C. Crosson,et al.  Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. , 2003, Investigative ophthalmology & visual science.

[4]  Terry Kim,et al.  Topical bevacizumab therapy for corneal neovascularization. , 2007, Archives of ophthalmology.

[5]  Mark R. Prausnitz,et al.  Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow Microneedles , 2010, Pharmaceutical Research.

[6]  D. Sanders,et al.  Inhibition of Experimental Angiogenesis of Cornea by Various Doses of Doxycycline and Combination of Triamcinolone Acetonide With Low-molecular-weight Heparin and Doxycycline , 2008, Cornea.

[7]  B. Acar,et al.  The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization , 2013, International Ophthalmology.

[8]  D. Gupta,et al.  Treatments for corneal neovascularization: a review. , 2011, Cornea.

[9]  Mark R. Prausnitz,et al.  Intrascleral Drug Delivery to the Eye Using Hollow Microneedles , 2009, Pharmaceutical Research.

[10]  B. Ambati,et al.  Horizons in therapy for corneal angiogenesis. , 2011, Ophthalmology.

[11]  M. Schwartzman,et al.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. , 2007, Prostaglandins & other lipid mediators.

[12]  Mark R. Prausnitz,et al.  Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.

[13]  R. Dana,et al.  Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. , 2010, Investigative ophthalmology & visual science.

[14]  A. Rouvas,et al.  Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. , 2008, American journal of ophthalmology.

[15]  M. Mohammadpour,et al.  Deep Intrastromal Bevacizumab Injection for Management of Corneal Stromal Vascularization After Deep Anterior Lamellar Keratoplasty, A Novel Technique , 2011, Cornea.

[16]  H. Tchah,et al.  The effect of topical bevacizumab on corneal neovascularization. , 2008, Ophthalmology.

[17]  F. Kruse,et al.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  Ryan F. Donnelly,et al.  Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety , 2010, Drug delivery.

[19]  H. Sasaki,et al.  Delivery of drugs to the eye by topical application , 1996, Progress in Retinal and Eye Research.

[20]  Chung-Tien Lin,et al.  Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. , 2009, Investigative ophthalmology & visual science.

[21]  J. Moan,et al.  Microneedle Pre-treatment of Human Skin Improves 5-Aminolevulininc Acid (ALA)- and 5-Aminolevulinic Acid Methyl Ester (MAL)-Induced PpIX Production for Topical Photodynamic Therapy Without Increase in Pain or Erythema , 2010, Pharmaceutical Research.

[22]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[23]  M. Prausnitz,et al.  Targeted Drug Delivery to the Eye Enabled by Microneedles , 2011 .

[24]  M. Prausnitz,et al.  Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. , 2012, Investigative ophthalmology & visual science.

[25]  H. Hurwitz,et al.  Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. , 2006, Seminars in oncology.

[26]  M. Allen,et al.  Microfabricated microneedles: a novel approach to transdermal drug delivery. , 1998, Journal of pharmaceutical sciences.

[27]  M. Prausnitz,et al.  Coated microneedles for drug delivery to the eye. , 2007, Investigative ophthalmology & visual science.

[28]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[29]  Rupak K Banerjee,et al.  Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[30]  Claus Cursiefen,et al.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[31]  Koen van der Maaden,et al.  Microneedle technologies for (trans)dermal drug and vaccine delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[33]  Mark R. Prausnitz,et al.  Coating Formulations for Microneedles , 2007, Pharmaceutical Research.

[34]  M. Erdurmuş,et al.  Subconjunctival bevacizumab for corneal neovascularization , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[35]  Terry Kim,et al.  Inhibition of Experimental Corneal Neovascularization by Using Subconjunctival Injection of Bevacizumab (Avastin) , 2008, Cornea.

[36]  B. Holden,et al.  Corneal thickness profiles in rabbits using an ultrasonic pachometer. , 1983, Investigative ophthalmology & visual science.

[37]  Mark R Prausnitz,et al.  Coated microneedles for transdermal delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[38]  I. Frazer,et al.  Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model , 2010, PloS one.

[39]  J. Matriano,et al.  Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis , 2010, Pharmaceutical Research.

[40]  M. Prausnitz,et al.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. , 1998, Journal of pharmaceutical sciences.

[41]  S. Yeung,et al.  Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization , 2011, Cornea.

[42]  W. Wee,et al.  Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy , 2009, Cornea.

[43]  Samirkumar R Patel,et al.  Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. , 2013, Investigative ophthalmology & visual science.

[44]  K. Bartz-Schmidt,et al.  Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.

[45]  M. Prausnitz,et al.  Particle‐Stabilized Emulsion Droplets for Gravity‐Mediated Targeting in the Posterior Segment of the Eye , 2014, Advanced healthcare materials.